Academia romana institutul de virusologie "stefan s. Nicolau"

Bibliografie

1. 
   Cozzi-Lepri A, Phillips A N, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS. 2008; 22 (16): 2187–2198.
   
2. 
   Phillips A N, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. The Lancet. 2007; 370 (9603): 1923–1928.
   
3. 
   Vercauteren J, Wensing AM, van de Vijver, DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struckh D, Schmith JC, Åsjö B, Bruckova M, Camacho R, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Rivah C, Ruiz L, Salminen M, Schuurman R, Sonnerborgh A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009; 1503-1508.
   
4. 
   Frentz D., Boucher C.A., van de Vijver D.A. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012; 14(1): 17-27.
   
5. 
   Op de Coul E, van den Burg R, Asjo B et al. Genetic evidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children. AIDS Res Hum Retroviruses. 2000; 16: 327–336.
   
6. 
   Triques K, Burgeois A, Saragosti S et al. High diversity of HIV-1 subtype F strains in Central Africa. Virology. 1999; 259: 99–109.
   
7. 
   Bello G, Afonso JM, Morgado MG. Phylodynamics of HIV-1 subtype F1 in Angola, Brazil and Romania. Infect Genet Evol. 2012; 12(5): 1079-1086.
   
8. 
   Guimarães ML, Velarde-Dunois KG, Segurondo D, Morgado MG. The HIV-1 epidemic in Bolivia is dominated by subtype B and CRF12_BF "family" strains. Virol J. 2012; 16: 9-19.
   
9. 
   Aulicino PC, Bello G, Guimaraes ML, Ruchansky D, Rocco C, Mangano A, Morgado MG. Longitudinal analysis of HIV-1 BF1 recombinant strains in vertically infected children from Argentina reveals a decrease in CRF12_BF pol gene mosaic patterns and high diversity of BF unique recombinant forms. Sen L Infect Genet Evol. 2011; 11(2): 349-357.
   
10. 
    Avila-Ríos S, Mejía-Villatoro CR, García-Morales C, Soto-Nava M, Escobar I, Mendizabal R, Girón A, García L, Reyes-Terán G. Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Rev Panam Salud Publica. 2011; 30(6): 641-648.
    
11. 
    Bandea CI, Ramos A, Pieniazek D, et al. Epidemiologic and evolutionary relationships between Romanian and Brazilian HIV-subtype F strains. Emerg Infect Dis. 1995; 1(3): 91–93.
    
12. 
    Guimaraes ML, Vicente AC, Otsuki K, et al. Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Retrovirology. 2009; 6: 39.
    
13. 
    Mbisa JL, Hué S, Buckton AJ, Myers RE, Duiculescu D, Ene L, Oprea C, Tardei G, Rugina S, Mardarescu M, Floch C, Notheis G, Zöhrer B, Cane PA, Pillay D. Phylodynamic and Phylogeographic Patterns of the HIV Type 1 Subtype F1 Parenteral Epidemic in Romania. AIDS Res Hum Retroviruses. 2012; 28(9): 961-966.
    
14. 
    Mehta SR, Wertheim JO, Delport W, Ene L, Tardei G, Duiculescu D, Kosakovsky Pond SL, Smith DM. Using Phylogeography to Characterize the Origins of the HIV-1 Subtype F Epidemic in Romania. Infect Genet Evol. 2011; 11(5): 975–979.
    
15. 
    Joint United Nations Programme on HIV/AIDS (UNAIDS). 2004. The Changing HIV/AIDS Epidemic in Europe and Central Asia. WHO Library, Geneva, http://data.unaids.org/Publications/IRC-pub06/jc1038-changingepidemic_en.pdf, accesat in mai 2014.
    
16. 
    L M Gonzalez, R M Brindeiro, M Tarin, A Calazans, M A Soares, S Cassol, and A Tanuri. The subtype C of human immunodeficiency virus type 1 protease presents an in vitro hypersusceptibility to protease inhibitor Lopinavir. Antimicrob. Agents Chemother. 2003; 47: 2817-2822.
    
17. 
    Jeeninga, R E, M Hoogenkamp, M Armand-Ugon, M de Baar, K Verhoef, and B Berkhout. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 2000; 74: 3740-3751.
    
18. 
    Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008; 13(2): 25-36.
    
19. 
    DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000; 5: 41-48.
    
20. 
    Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347: 385–394.
    
21. 
    Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008; 197: 867–870.
    
22. 
    Janet D Siliciano and Robert F Siliciano. Recent trends in HIV-1 drug resistance. Current Opinion in Virology. 2013; 3: 487–494.